IGF::OT::IGF A MULTICENTER PHASE II STUDY OF DOCOSAHEXAENOIC ACID IN PATIENTS WITH A HISTORY OF BREAST CANCER, PREMALIGNANT LESIONS, OR BENIGN BREAST DISEASE
IGF::OT::IGF 对有乳腺癌、癌前病变或良性乳腺疾病病史的患者进行的二十二碳六烯酸多中心 II 期研究
基本信息
- 批准号:9162629
- 负责人:
- 金额:$ 5.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-19 至 2016-03-18
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAdipocytesAdipose tissueAnimalsAnti-Inflammatory AgentsAnti-inflammatoryAromataseBenignBiological MarkersBlood CirculationBreastBreast DiseasesBudgetsDataDental crownsDietDietary FactorsDietary InterventionDinoprostoneDocosahexaenoic AcidsEligibility DeterminationEnrollmentEnzymesEpidemiologic StudiesEstrogensEvaluationExerciseFatty AcidsFatty acid glycerol estersFish OilsGeneral PopulationGoalsGonadal Steroid HormonesGrowth FactorHormone ReceptorInflammationInflammation MediatorsInstitutionInterleukin-6LesionMalignant NeoplasmsMammaplastyMammary Gland ParenchymaMammary NeoplasmsMammary glandMedicineMusNecrosisObesityOmega-3 Fatty AcidsOverweightPTGS2 geneParticipantPatientsPhasePostmenopausePremalignantPreventionProductionPropertyProtocols documentationRNARecording of previous eventsRiskRisk FactorsSamplingSignal TransductionSourceSpecimenStructureTumor Necrosis Factor-alphaUpdateValidationVisceralWomancancer riskfeedingmacrophagemalignant breast neoplasmmortalitymouse modeloutcome forecastpatient populationphase 2 studyresponsetargeted treatmenttranscription factortumor progression
项目摘要
Obesity is a risk factor for hormone receptor (HR)-positive breast cancers and particular subtypes of HR-negative breast cancers, such as basal-like cancers. Adiposity may increase breast cancer risk through multiple mechanisms, including elevating post-menopausal production of sex-steroids, growth factors and inflammation Obesity is associated with subclinical inflammation in adipose tissue. Data from mouse models and studies of women, suggest that obesity is associated with formation “crown-like structures (CLS)”, which are composed of macrophages encircling necrotic adipocytes. These macrophages produce a variety of pro-inflammatory mediators. In obese women, increased levels of pro-inflammatory mediators are commonly found in the circulation and may contribute to breast cancer progression and mortality. In diet and genetically induced mouse models of obesity, CLS form in the adipose tissue of the mouse mammary gland and visceral fat. Importantly, the presence of CLS was associated with increased levels of several pro-inflammatory mediators (TNF-α, IL-1β, Cox-2, PGE2) and activation of the NF-κB transcription factor. These changes were paralleled by elevated levels of aromatase, the rate-limiting enzyme for estrogen synthesis, in both the mammary gland and visceral fat. Independent validation of the associations between obesity, CLS and inflammation in breast adipose and expression of pro-inflammatory mediators (including IL-6) was recently provided by a group from UNC, Chapel Hill who studied women undergoing reduction mammoplasty specimens (n=74). Overall, these results support the existence of an obesity-inflammation-aromatase axis that may contribute to the increased risk of breast cancer in obese women, and a worse prognosis. Docosahexaenoic acid, an omega-3 fatty acid in fish oil, can suppress levels of inflammatory mediators including TNF-α and COX-2. In feeding studies, it has been shown that treatment with DHA can also reduce levels of aromatase in the mouse mammary gland. Consistent with these findings, diets rich in fish oil, a source of omega-3 fatty acids, have been associated with a reduced risk of a number of malignancies including breast cancer and similar diets protect against experimentally induced mammary cancer in animals. In the general population, omega-3 fatty acid supplements, such as DHA are widely used but the underlying mechanisms of action are incompletely understood. Consistent with targeted therapies, dietary factors including omega-3 fatty acids may only be beneficial in subsets of patients. This would make it difficult to detect a consistent clinically important signal in epidemiological studies. It is likely that nutritional interventions like medicines will need to be personalized. Taken together, these observations emphasize the importance of determining whether DHA possesses anti-inflammatory properties in the breast tissue of overweight and obese women.
肥胖是激素受体(HR)阳性乳腺癌和特定亚型的HR阴性乳腺癌(如基底样癌)的危险因素。肥胖可能通过多种机制增加乳腺癌风险,包括提高绝经后性类固醇、生长因子和炎症的产生。肥胖与脂肪组织的亚临床炎症有关。来自小鼠模型和女性研究的数据表明,肥胖与形成“冠状结构(CLS)”有关,CLS由巨噬细胞包围坏死脂肪细胞组成。这些巨噬细胞产生多种促炎介质。在肥胖妇女中,促炎介质水平的增加通常在循环中发现,并可能导致乳腺癌的进展和死亡。在饮食和基因诱导的肥胖小鼠模型中,CLS在小鼠乳腺和内脏脂肪的脂肪组织中形成。重要的是,CLS的存在与几种促炎介质(TNF-α, IL-1β, Cox-2, PGE2)水平升高以及NF-κB转录因子的激活有关。这些变化与乳腺和内脏脂肪中芳香化酶(雌激素合成的限速酶)水平升高相一致。最近,来自教堂山UNC的一个研究小组对接受乳房缩小成形术的妇女进行了研究,对肥胖、CLS和乳腺脂肪炎症以及促炎介质(包括IL-6)的表达之间的关系进行了独立验证。总的来说,这些结果支持肥胖-炎症-芳香化酶轴的存在,这可能导致肥胖女性患乳腺癌的风险增加,预后更差。二十二碳六烯酸是鱼油中的一种omega-3脂肪酸,可以抑制炎症介质的水平,包括TNF-α和COX-2。在喂养研究中,已经证明DHA处理也可以降低小鼠乳腺中芳香化酶的水平。与这些发现一致的是,富含鱼油(omega-3脂肪酸的一种来源)的饮食与降低包括乳腺癌在内的许多恶性肿瘤的风险有关,类似的饮食可以预防实验诱导的动物乳腺癌。在一般人群中,omega-3脂肪酸补充剂,如DHA被广泛使用,但其潜在的作用机制尚不完全清楚。与靶向治疗一致,包括omega-3脂肪酸在内的饮食因素可能只对部分患者有益。这将使在流行病学研究中难以发现一致的临床重要信号。像药物这样的营养干预措施很可能需要个性化。综上所述,这些观察结果强调了确定DHA是否在超重和肥胖女性的乳房组织中具有抗炎特性的重要性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
POWEL BROWN其他文献
POWEL BROWN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('POWEL BROWN', 18)}}的其他基金
PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE BIOMARKERS; TASK ORDER: PREVENTION OF COLORECTAL CANCER WITH IPSC-
预防临床前药物开发计划:临床前疗效和中间生物标志物;
- 批准号:
10412368 - 财政年份:2021
- 资助金额:
$ 5.59万 - 项目类别:
TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION
任务顺序:CD73 抑制剂用于胰腺癌免疫预防的临床前测试
- 批准号:
10269157 - 财政年份:2020
- 资助金额:
$ 5.59万 - 项目类别:
TASK ORDER: PRECLINICAL TESTING OF CD73 INHIBITORS FOR PANCREATIC CANCER IMMUNOPREVENTION
任务顺序:CD73 抑制剂用于胰腺癌免疫预防的临床前测试
- 批准号:
10451453 - 财政年份:2020
- 资助金额:
$ 5.59万 - 项目类别:
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
其他功能 - 癌症预防剂开发计划:早期临床研究
- 批准号:
10425187 - 财政年份:2019
- 资助金额:
$ 5.59万 - 项目类别:
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
其他功能 - 癌症预防剂开发计划:早期临床研究
- 批准号:
10691840 - 财政年份:2019
- 资助金额:
$ 5.59万 - 项目类别:
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
其他功能 - 癌症预防剂开发计划:早期临床研究
- 批准号:
10045663 - 财政年份:2019
- 资助金额:
$ 5.59万 - 项目类别:
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
其他功能 - 癌症预防剂开发计划:早期临床研究
- 批准号:
10901815 - 财政年份:2019
- 资助金额:
$ 5.59万 - 项目类别:
A PHASE I DOSE ESCALATION STUDY OF TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER
乳腺癌高危女性局部使用贝沙罗汀的 I 期剂量递增研究
- 批准号:
10251826 - 财政年份:2017
- 资助金额:
$ 5.59万 - 项目类别:
IGF::OT::IGF DETERMINATION OF DOSING REGIMENS OF ERLOTINIB IN COMBINATION WITH SULINDAC FOR PREVENTION OF COLORECTAL CANCER WHILE REDUCING AGENT TOXICITY POP 06/01/2017 - 05/31/2019
IGF::OT::IGF 确定厄洛替尼联合舒林酸预防结直肠癌同时降低药物毒性的给药方案 POP 06/01/2017 - 05/31/2019
- 批准号:
9566448 - 财政年份:2017
- 资助金额:
$ 5.59万 - 项目类别:
A PHASE I DOSE ESCALATION STUDY OF TOPICAL BEXAROTENE IN WOMEN AT HIGH RISK FOR BREAST CANCER
乳腺癌高危女性局部使用贝沙罗汀的 I 期剂量递增研究
- 批准号:
9915578 - 财政年份:2017
- 资助金额:
$ 5.59万 - 项目类别:
相似国自然基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制
- 批准号:81970721
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
Recruitment of brown adipocytes in visceral white adipose tissue by fibroblast growth factor 8b
成纤维细胞生长因子 8b 将棕色脂肪细胞募集到内脏白色脂肪组织中
- 批准号:
321208980 - 财政年份:2016
- 资助金额:
$ 5.59万 - 项目类别:
Research Grants
Enhancing Energy Expending Adipocytes in White Adipose Tissue
增强白色脂肪组织中的能量消耗脂肪细胞
- 批准号:
8827438 - 财政年份:2014
- 资助金额:
$ 5.59万 - 项目类别:
Induction of brown-like adipocytes in white adipose tissue by food-derived factors
食物源性因子在白色脂肪组织中诱导棕色样脂肪细胞
- 批准号:
26450168 - 财政年份:2014
- 资助金额:
$ 5.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
WAT-on-a-chip - Development of a micofluidic, microphysiologic in vitro adipose tissue model for high-throughput drug screening based on hiPSC-derived adipocytes.
WAT-on-a-chip - 开发微流体、微生理体外脂肪组织模型,用于基于 hiPSC 衍生脂肪细胞的高通量药物筛选。
- 批准号:
257256526 - 财政年份:2014
- 资助金额:
$ 5.59万 - 项目类别:
Research Fellowships
Enhancing Energy Expending Adipocytes in White Adipose Tissue
增强白色脂肪组织中的能量消耗脂肪细胞
- 批准号:
8828181 - 财政年份:2013
- 资助金额:
$ 5.59万 - 项目类别:
Enhancing Energy Expending Adipocytes in White Adipose Tissue
增强白色脂肪组织中的能量消耗脂肪细胞
- 批准号:
8520690 - 财政年份:2013
- 资助金额:
$ 5.59万 - 项目类别:
Enhancing Energy Expending Adipocytes in White Adipose Tissue
增强白色脂肪组织中的能量消耗脂肪细胞
- 批准号:
8629741 - 财政年份:2013
- 资助金额:
$ 5.59万 - 项目类别:
Effect of exercise training on formation of brite adipocytes within white adipose tissue
运动训练对白色脂肪组织内脂肪细胞形成的影响
- 批准号:
23700778 - 财政年份:2011
- 资助金额:
$ 5.59万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Investigation for the mechanisms of the emergence of brown adipocytes in white adipose tissue
白色脂肪组织中棕色脂肪细胞出现机制的研究
- 批准号:
21780261 - 财政年份:2009
- 资助金额:
$ 5.59万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
LOUISIANA COBRE: P1: INDUCE THERMOGENIC BROWN ADIPOCYTES IN WHITE ADIPOSE TISSUE
路易斯安那 COBRE:P1:在白色脂肪组织中诱导产热棕色脂肪细胞
- 批准号:
7610781 - 财政年份:2007
- 资助金额:
$ 5.59万 - 项目类别: